Literature DB >> 18923736

The human papillomavirus vaccine: The promise of cervical cancer prevention.

Bl Johnston1, Jm Conly.   

Abstract

Entities:  

Year:  2007        PMID： 18923736      PMCID： PMC2533627          DOI： 10.1155/2007/305240

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  26 in total

Review 1.  Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.

Authors:  Geoffrey P Garnett
Journal:  J Infect Dis       Date:  2005-02-01       Impact factor: 5.226

2.  An analytical framework for immunization programs in Canada.

Authors:  L J Erickson; P De Wals; L Farand
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

3.  Debate begins over public funding for HPV vaccine.

Authors:  Pauline Comeau
Journal:  CMAJ       Date:  2007-03-20       Impact factor: 8.262

4.  HPV vaccination--more answers, more questions.

Authors:  George F Sawaya; Karen Smith-McCune
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

Review 5.  Immune responses to human papillomavirus.

Authors:  Margaret Stanley
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

6.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

7.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

10.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.